The study, published Oct. 11 in Cell Reports Medicine, analyzed metformin on a genetic level. It found the drug targeted 30 genes associated with afib, with direct effects on gene expression for eight.
“Finding drugs or procedures to treat atrial fibrillation is difficult because of potential serious side effects,” Mina Chung, MD, a senior author on the study, said in an Oct. 11 release from Cleveland Clinic. “There is a significant need for new treatments for atrial fibrillation as there have been no new drugs approved in more than a decade.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
